Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) has reported the market launch in the US of its sodium phenylacetate and sodium benzoate (SPSB) liquid product, the only 20ml version available on the market. The product is being launched by its partner MAIA Pharmaceuticals Inc. (MAIA), a specialty pharmaceutical company based in Princeton, New Jersey.
Product Details and Market Need
Fosun and MAIA’s 20ml SPSB liquid product is designed to address a significant market need. Previously, only 50ml vials were available, leading to extensive product wastage when used in pediatric settings. The 20ml vial size offers a more efficient and practical solution for healthcare providers.
Indications and Therapeutic Use
SPSB is a nitrogen-binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia (excessive ammonia) and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle. The launch of the 20ml version aims to improve treatment options and reduce waste, particularly in pediatric care.
Future Outlook
The US market launch of the 20ml SPSB liquid product underscores Fosun Pharma’s commitment to addressing unmet medical needs and enhancing patient care. By offering a more suitable vial size, the company aims to optimize treatment protocols and improve outcomes for patients with urea cycle disorders.-Fineline Info & Tech
